No magic pill, Pg10

Key Highlights:

• India faces a dual challenge of persistent undernutrition and rapidly increasing obesity, with a significant portion of the population being metabolically unhealthy.
• Semaglutide, a GLP-1 receptor antagonist drug initially approved for diabetes treatment in India in 2022, has gained popularity in the weight-loss industry.
• The Indian anti-obesity drug market reached Rs 600 crore in June 2023, with GLP-1 drugs comprising about 75% of the market share.
• Semaglutide offers health benefits such as weight loss, improved blood sugar control, and reduced cardiovascular risks, but also poses side effects like nausea, vomiting, and potential long-term risks.

Detailed Insights:

• The rise of semaglutide in India's weight-loss market could shift resources away from cost-effective public health initiatives focused on diet, exercise, and preventive health.
• Semaglutide treatment costs approximately Rs 2,00,000 per year for a 12-13 kg weight loss, while diet and exercise cost around Rs 40,000 per year for a 6-8 kg weight loss, highlighting the economic disparity.
• Weak enforcement in India may lead to over-the-counter misuse and unsafe online sourcing of semaglutide, potentially increasing the divide in healthcare access between the wealthy and low-income populations.
• Integrating semaglutide into public health programs and implementing price controls after the 2026 patent expiry could ensure equitable access and prevent the drug from overshadowing traditional, cheaper options.

Key Concepts Involved:

• Obesity: A condition characterized by excessive body fat accumulation that may impair health.
• GLP-1 Receptor Antagonists: A class of drugs that mimic the effects of incretin hormones to lower blood sugar levels and promote weight loss.
• Metabolic Health: The state of having ideal levels of blood sugar, triglycerides, high-density lipoprotein (HDL) cholesterol, blood pressure, and waist circumference, without using medications.